Clinical Trial Update: A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating patritumab deruxtecan for brain metastases has been withdrawn from ClinicalTrials.gov.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases

Drugs mentioned

• Patritumab Deruxtecan (patritumab deruxtecan)

Snippet

Sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Conditions: Brain Metastases, Adult | Phase 2 | Status: WITHDRAWN